Sigrid Therapeutics is developing an ingested medical device for lowering blood sugar in prediabetics.
Sigrid Therapeutics has raised €12M across 3 funding rounds from 9 investors, most recently a round in Jan 2026. Based in Stockholm, Sweden; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-01-07 | Other | €4.3M | undisclosed investors | View deal → |
| 2023-01-17 | Other | €536k | Mattias Ankarberg,Private Investors | View deal → |
| 2021-11-10 | Other | €7.2M | Barbara Bergström,Crosslight Partners,Hans Bergström,Irrus Investments,Joyance Partners,Matsson family | View deal → |
